Why Even Presidential Pressure Might Not Get More Vaccine to Market Faster
Even invoking the widely heralded Defense Production Act to pressure drugmakers wouldn’t overcome vast obstacles.
Showing 101 - 110 of 110
-
-
Commentary
Eureka! Two Vaccines Work — But What About the Also-Rans in the Pharma Arms Race?
How two effective vaccines on the market make it so much harder to quickly test any competing vaccines.
By Arthur Allen -
Pediatricians Want Kids to Be Part of COVID Vaccine Trials
Some years from now, infants and school-aged children will probably be the mainstay of a universal vaccination program against COVID-19 in the United States. But first, doctors want to be sure that newfangled vaccines won’t harm them.
By Arthur Allen -
Government-Funded Scientists Laid the Groundwork for Billion-Dollar Vaccines
Drugmakers will walk away with massive profits, but much of the pioneering work on mRNA vaccines was done with government money.
By Arthur Allen -
Five Important Questions About Pfizer’s COVID-19 Vaccine
The drugmaker says its mRNA vaccine worked in 90% of patients in its trial, but some observers question how long immunity will last and who will benefit.
By Arthur Allen -
NIH ‘Very Concerned’ About Serious Side Effect in Coronavirus Vaccine Trial
The AstraZeneca trial is on hold in the U.S. as scientists try to unravel whether a rare neurological condition is linked to the vaccine. But regulators are frustrated by a lack of information from the drugmaker.
By Arthur Allen and Liz Szabo -
LA Hospital Seeks Vaccine Trial Participants Among Its Own High-Risk Patients
Harbor-UCLA Medical Center serves patients who are especially vulnerable to the coronavirus: They are essential workers, have chronic diseases and are members of underrepresented racial and ethnic groups. When the safety-net hospital kicks off enrollment for its COVID-19 vaccine trial Wednesday, it will look to those patients to participate.
By Arthur Allen -
Trust, Fear and Solidarity Will Determine the Success of a COVID Vaccine
Polio terrified Americans, and in 1955, when Jonas Salk’s vaccine became available, they snapped it up like candy. Sixty-five years later, COVID is the latest dread virus, but many undercurrents could inhibit its acceptance.
By Arthur Allen -
Public Health Experts Fear a Hasty FDA Signoff on Vaccine
The FDA must approve any coronavirus vaccine before it’s widely distributed, but political pressure could cloud the decision.
By Arthur Allen -
Analysis: Get Ready For The Vaccine — They’re Never Simple
Trials are an immense undertaking involving tens of thousands of participants. They’re likely to start this summer — but don’t expect quick results. And what’s a successful result, anyway?
By Arthur Allen
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: